MOTIVATE Weight Loss Study (MOTIVATE)

April 1, 2015 updated by: USGI Medical

Evaluating MOTIlity, Hormonal Impact, Satiety, and Weight Changes With VArying Procedural TEchniques Utilizing the Incisionless Operating Platform for the Treatment of Primary Obesity

The purpose of this study is to evaluate the impact of minor variations in Incisionless Operating Platform (IOP)procedural techniques on gastric emptying, hormone levels, satiety, and weight loss in the treatment of primary obesity. It will confirm, in an open prospective study, the action mechanisms for the "POSE" endoscopic treatment technique for obesity, and it will help determine if they are maintained at least 6 months following the procedure. Durability of weight loss will be tracked through post-POSE visits up to 18 months following the procedure.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

18

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Catalonia
      • Barcelona, Catalonia, Spain, 08022
        • Centro Médico

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Has a BMI of >30 and <40
  2. Male or female ≥21 yrs. of age and < 60 yrs. of age at time of enrollment
  3. Patient has had no significant weight change (+/- 5% of total body weight) in last 6 months but has been able to lose significant weight in the past with diet and exercise.
  4. Is a reasonable candidate for general anesthesia
  5. Agrees not to have any additional weight loss interventional procedures or liposuction for at least 18 months following study enrollment and agrees not to take any prescription or over the counter weight loss medications for at least 1 year.
  6. Physically and mentally able to comply with the visit schedule, ancillary testing, and behavior modification (diet and exercise) required for the study and agrees to study commitment requirements
  7. Had successful completion of the pre-screening, nutritional and educational programs and psychological assessment supporting that the subject is an appropriate bariatric surgical candidate

Exclusion Criteria:

  1. History of (or intra-operative evidence of) bariatric, gastric or esophageal surgery
  2. Esophageal stricture or other anatomy and/or condition that could preclude passage of endoluminal instruments
  3. Moderate to severe Gastro-esophageal reflux disease (GERD)
  4. Known hiatal hernia >3cm by history or as determined by UGI exam or endoscopy
  5. Known GI motility disorder or pancreatic insufficiency/disease
  6. Intra-operative Exclusion: Active peptic ulcer or hiatal hernia >3cm
  7. Pregnancy.
  8. Present Corticosteroid Use
  9. History of inflammatory disease of GI tract
  10. Severe coagulopathies, hepatic insufficiency or cirrhosis
  11. History or present use of insulin or insulin derivatives for treatment of diabetes
  12. Had Type II Diabetes Mellitus (as defined by HgbA1c >6.0) for greater than 2 years at the time of enrollment
  13. Uncontrolled Type II DM (HgbA1c >7.0 at screening)
  14. Patient has quit smoking within last 6 months at time of enrollment or plans to quit smoking in the next year
  15. Patient has a history of drug or alcohol abuse or actively abusing either
  16. Patient is presently being treated with medication for depression, psychosis, or other mood or eating disorder
  17. Non-ambulatory or has significant impairment of mobility
  18. Works for, or is first degree relative of investigator, study institution, or support staff involved in the study.
  19. Known hormonal or genetic cause for obesity
  20. Participating in another clinical study
  21. Patient is on medications known to impact GI motility or gut hormones that cannot be discontinued prior to nuclear testing
  22. Have work hours, family obligations or transportation issues that could interfere with patient returning for all scheduled evaluations, tests and nutritional counseling.
  23. Lives >60 kilometers from investigator site.
  24. Patient is not able to provide written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Continuous Horizontal row
Use the IOP system from USGI to install suture anchors running from the distal body into the proximal antrum

Sutures are placed in the distal body in one of three randomized techniques:

"A" = reduction in "ring" opening to antrum using plications "B" = continuous horizontal row, running from distal body into proximal antrum "C" = Control. Current V shape as Control

Other Names:
  • The g-Cath EZ Suture Anchor Delivery Catheter
Experimental: Reduction in "ring" opening
Use the IOP system from USGI to install suture anchors to reduce the "ring" opening to the antrum

Sutures are placed in the distal body in one of three randomized techniques:

"A" = reduction in "ring" opening to antrum using plications "B" = continuous horizontal row, running from distal body into proximal antrum "C" = Control. Current V shape as Control

Other Names:
  • The g-Cath EZ Suture Anchor Delivery Catheter
Experimental: Control Arm
Use the IOP system from USGI to install suture anchors in the Current V shape in distal body

Sutures are placed in the distal body in one of three randomized techniques:

"A" = reduction in "ring" opening to antrum using plications "B" = continuous horizontal row, running from distal body into proximal antrum "C" = Control. Current V shape as Control

Other Names:
  • The g-Cath EZ Suture Anchor Delivery Catheter

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weight Loss
Time Frame: Monthly post procedure out to 18 months
Each patient's weight will be measured and recorded on a monthly basis out to 18 months post procedure
Monthly post procedure out to 18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fasting/Post-prandial Peptides
Time Frame: pre-procedure & 8 weeks post procedure
  1. Samples to be collected when fasting and 30, 60, 90, and 120 minutes after a standard meal (a meal consisting of 400 calories), The meal must be consumed within 10 minutes.. Serum collection tubes will be centrifuged immediately at 4°C for 10 minutes at 3600rpm and stored at -20°C
  2. Samples to be collected by ELISA are: C-peptide, serum insulin, glucose, PYY, GLP-1 (active), leptin, and GIP. Total ghrelin level to be analyzed by RIA.
pre-procedure & 8 weeks post procedure

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gastric Emptying
Time Frame: Pre-procedure & 2 & 6 months post procedure
This test consists of determining the duration of a radioactive marker in a stomach, which is non-absorbable, and free of any food components.
Pre-procedure & 2 & 6 months post procedure
Satiety Testing
Time Frame: Pre-procedure & 2 & 6 months post procedure
The subjects ingest a nutritional drink (Ensure) at a constant rate of 30 mL per minute, constantly filling the glass with a perfusion pump (Gemini PC-2, IMED, San Diego, CA). (The subjects are not conscious of the volume being ingested.) The subjects are instructed to maintain consumption at the fill rate. Participants take note of their sensation of satiety with a graphical classification scale, which combines verbal descriptors on a scale of 0 to 5 (0 = no symptoms, 1 = first sensation of fullness [threshold]; 2 = light, 3 = moderate, 4 = severe, and 5 = maximum fullness or unbearable). The participants are told to stop taking the food product when a score of 5 is obtained. The maximum consumption of volume of the nutritional drink is recorded.
Pre-procedure & 2 & 6 months post procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Jorge C. Espinos, MD, Centro Médico Teknon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2012

Primary Completion (Actual)

August 1, 2013

Study Completion (Actual)

August 1, 2013

Study Registration Dates

First Submitted

August 31, 2012

First Submitted That Met QC Criteria

August 31, 2012

First Posted (Estimate)

September 5, 2012

Study Record Updates

Last Update Posted (Estimate)

April 3, 2015

Last Update Submitted That Met QC Criteria

April 1, 2015

Last Verified

April 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • TPR600

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Using The IOP system from USGI to place suture anchors

Subscribe